Advanced glycation and ROS: A link between diabetes and heart failure

Current Vascular Pharmacology

Volumn 6, Issue 1, 2008, Pages 44-51

  Rojas, Armando ^a   Mercadal, Enrique ^a   Figueroa, Hector ^a   Morales, Miguel A ^b  

^a UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Advanced glycation; Cardiomyocytes; Diabetes; Glucose imbalance; Heart failure; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ANTIOXIDANT; BENFOTIAMINE; CARVEDILOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MATRIX METALLOPROTEINASE; PHOSPHOLIPASE D; REACTIVE OXYGEN METABOLITE; RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

AMADORI REARRANGEMENT; APOPTOSIS; ATHEROSCLEROSIS; CELL FUNCTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; GENE EXPRESSION; GLYCATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; HYPERGLYCEMIA; NONHUMAN; OXIDATIVE STRESS; PROTEIN CROSS LINKING; REVIEW; ANIMAL; CARDIOMEGALY; HEART; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOMEGALY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES; VENTRICULAR REMODELING;

EID: 43249101701     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108783331312     Document Type: Review

References (130)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Members of the Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2006 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2006; 113: 85-151.
2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1 397-402.
3. Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003; 2:1 doi:10.1186/1475-2840-2-1.
4. Bell DSH. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-41.
5. Smith NL, Burke GL, Tracy R, Savage PJ, Carlson M. The association of fasting glucose levels with congestive heart failure in diabetic adults > or = 65 years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2236-41.
6. Gregory A, Nichols GA, Gullion CM, Koro C, Ephross SE, Brown JB, et al. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care 2004; 27: 1879-84.
7. King G, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-70.
8. Bierman E. George Lyman Duff Memorial Lecture: Atherogenesis in diabetes. Arterioscler Thromb 1992; 12: 647-56.
9. Krolewski A, Kosinski E, Warram J, Leland O, Busick E, Asmal A, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-5.
10. Nelson C, Lange T. Blood glucose and heart failure in nondiabetic patients. Diabetes Care 2005; 28: 607-11.
11. Ramasamy R, Vannucci SJ, Du Yan SS, Herold K, Fang Yan S, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration and inflammation. Glyciobiology 2005; 15: 16-28.
12. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992, 23 1-34.
13. Yaylayan VA, Huyghues-Despointes A. Chemistry of Amadori rearrangement products: analysis, synthesis, kinetics, reactions, and spectroscopic properties. Crit Rev Food Sci Nutr 1994; 34: 321-69.
14. Zyzak DV, Richardson JM, Thorpe SR, Baynes JW. Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch Biochem Biophys 1995; 316: 547-54.
15. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible processes for aging of long-lived proteins. Science 1981; 211: 491-3.
16. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
17. Sell DR, Monnier VM. Structure elucidation of a senescence crosslink from human extracellular matrix: implications of pentoses in the aging process. J Biol Chem 1994; 264: 21597-602.
18. Ledl F, Schleicher E. New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl 1989; 29: 565-94.
19. Maillard LC. Action des acides amines sur les sucres: formation des melaniodines par voie methodique. C R Academy Sciences 1912; 154: 66-8.
20. Ahmed M, Thorpe SR, Bynes JW. Identification of N ω(carboxymethyl)lysine as a degradation product of fructoselysine in glycated proteins. J Biol Chem 1986; 61: 4889-94.
21. Sell DR, Monnier VM. Structure elucidation of a senescence crosslink from human extracellular matrix: implications of pentoses in the aging process. J Biol Chem 1989; 264: 21597-602.
22. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978; 220: 21-7.
23. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
24. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-9.
25. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007; 9: 233-245.
26. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thrope SR, Baynes JW, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-78.
27. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of AGEs with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
28. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991; 174: 515-24.
29. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
30. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
31. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1501-15.
32. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-97.
33. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of AGEs with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
34. Lander NM, Tauras JM, Ogiste JS, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation endproducts triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-14.
35. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end-products: Sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
36. Rojas A, Morales MA. Advanced glycation and endothelial functions: A link towards vascular complications in diabetes. Life Sci 2004; 76: 715-30.
37. Li SY, Sigmon VK, Babcock SA, Ren J. Advanced glycation end-product induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci 2007; 80: 1051-6.
38. Casselmann A, Reimann I, Friedrich A, Schubert RE, Silber A, Simm C. Age-dependent expression of advanced glycation end product receptor genes in the human heart. Gerontology 2004; 50: 127-34.
39. Wenzel S, Rohde C, Wingeming S, Roth J, Kojda G, Schluter KD. Lack of endothelial NO synthase-derived NO formation favours hypertrophy in adult ventricular cardiomyocytes. Hypertension 2007; 49: 193-200.
40. Rojas A, Romay S, González D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end-products. Circ Res 2000; 86: 50-4.
41. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure J Mol Cell. Cardiol 2002; 34: 379-88.
42. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41: 2164-71.
43. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999; 85: 357-63.
44. Sawyer DB, Colucci WS. Mitochondrial oxidative stress in heart failure: "oxygen wastage" revisited. Circ Res 2000; 86: 119-20.
45. McMurray J, McLay J, Chopra M, Bridges A, Belch JJF. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 65: 1261-2.
46. Singh N, Dhalla AK, Seneviratne C, Signal PK. Oxidative stress and heart failure. Mol Cell Biochem 1995; 147: 77-81
47. Ellis GR, Anderson RA, Lang D, Blackman DJ, Mornis RHK, Morris-Thurgood J, et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. J Am Coll Cardiol 2000; 36: 1474-82.
48. Rojas A, Figueroa H, Morales MA, Re L. Facing up the ROS labyrinth- Where to go? Curr Vasc Pharmacol 2006; 4: 277-89.
49. King MK, Coker ML, Goldberg A, McElmurray JH 3rd, Gunasinghe HR, Mukherjee R, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res 2003; 92: 177-85.
50. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001; 89: 279-86.
51. Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 2003; 5: 789-94.
52. Sugden PH, Clerk A. Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid Redox Signal 2006; 8: 2111-24.
53. Daoud S, Schinzel R, Neumann A, Loske C, Fraccarollo D, Diez C, et al. Advanced glycation endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Mol Med 2001; 7: 543-51.
54. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K, et al. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 1999; 85: 147-53.
55. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280: C53-C60.
56. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10.
57. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998; 82: 482-95.
58. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-8.
59. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50: 1495-504.
60. Rodriguez-Ayala E, Anderstam B, Suliman EM, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P. Enhanced rage-mediated NFκB stimulation in inflamed hemodialysis patients. Atherosclerosis 2005; 180: 333-40.
61. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003; 104: 722-7.
62. Narula J, Haider N, Arbustini B, Chandrashekhar Y. Mechanisms of disease: apoptosis in heart failure - seeing hope in death. Nat Clin Pract Cardiovasc Med 2006; 3: 681-8.
63. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001; 89: 279-86.
64. Sugden PH, Clerk A. Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid Redox Signal 2006; 8: 2111-24.
65. Zieman SJ, Kass DA. Advanced glycation end-product crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64: 459-70.
66. Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999; 48: 1443-7.
67. Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, et al. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 2002; 34: 1425-31.
68. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and post-challenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25: 1845-50.
69. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006; 29: 26-31.
70. Fernandes VR, Cheng S, Lima JA. Atherosclerosis imaging and heart failure. Heart Fail Rev 2006; 11: 279-88.
71. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24: 1620-3.
72. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-7.
73. Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D, Belvito C, et al. -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 2005; 354: 111-6.
74. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation end-products (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005; 25: 879-82.
75. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993; 71: 26B-31B
76. Baynes JW, Thorpe SR. Glycoxidation and hipoxidation in atherogenesis. Free Radical Biol Med 2000; 28: 1708-16.
77. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-67.
78. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, et al. Suppression of Rage as a basis of simvastatin-dependent plaque stabilization in Type 2 Diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 2716-23.
79. Chen K, Thomas SR, Keaney JF Jr. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic Biol Med 2003; 35: 117-32.
80. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
81. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006; 113: 1226-34.
82. Zima AV, Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006; 71: 310-21.
83. Guerra L, Cerbai E, Gessi S, Borea PA, Mugelli A. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea-pig ventricular myocytes. Br J Pharmacol 1996; 118: 1278-84.
84. Kaplan P, Babusikova E, Lehotsky J, Dobrota D. Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem 2003; 248: 41-7.
85. Nakaya H, Takeda Y, Tohse N, Kanno M. Mechanism of the membrane depolarization induced by oxidative stress in guinea-pig ventricular cells. J Mol Cell Cardiol 1992; 24: 523-34.
86. He X, Liu Y, Sharma V, Dirksen RT, Waugh R, Sheu SS, et al. ASK1 associates with troponin T and induces troponin T phosphorylation and contractile dysfunction in cardiomyocytes. Am J Pathol 2003; 163: 243-51.
87. Eskildsen-Helmond YE, Van Heugten HA, Lamers JM. Regulation and functional significance of phospholipase D in myocardium. Mol Cell Biochem 1996; 157: 39-48.
88. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med 2006; 41: 349-61.
89. Fang ZY, Prins JB, Marwick, TM. Diabetic cardiomyopathy: evidence, mechanisms and therapeutic implications. Endocr Rev 2004; 25: 543-67.
90. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
91. Asahi K, Ichimori K, Nakazawa H, Izuhara Y, Inagi R, Watanabe T, et al. Nitric oxide inhibits the formation of advanced glycation end products. Kidney Int 2000; 58: 1780-87.
92. Frank GD, Eguchi S, Motley ED. The role of reactive oxygen species in insulin signaling in the vasculature. Antioxid Redox Signal 2005; 7: 1053-61.
93. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25: 1055-59.
94. Hogan M, Cerami A, Bucala R. Advanced glycosylation end products block the antiproliferative effect of nitric oxide: role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1110-5.
95. Xu B, Chibber R, Ruggerio D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-91.
96. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47: 945-52.
97. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41: 1435-41.
98. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear factor- B in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49: 1561-70.
99. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
100. Nilsson BO. Biological effects of aminoguanidine: an update. Inflamm Res 1999; 48: 509-15.
101. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 9: 31-40.
102. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-46.
103. Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002; 11: 565-74.
104. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-87.
105. Sebekova K, Gazdikova K, Syrova D, Blazicek P, Schinzel R, Heidland A, et al. Effects of ramipril in non-diabetic nephropathy: improved parameters of oxidative stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003; 17: 265-70.
106. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-22.
107. Sobala G, Menzel EJ, Sinzinger H. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem Pharmacol 2001; 61: 373-9.
108. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycaemic damage and prevents experimental diabetic retinopathy. Nature Med 2003; 9: 294-9.
109. Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 2006; 100: 150-6.
110. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212: 167-78.
111. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006; 55: 798-805.
112. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003; 52: 777-83.
113. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004; 53: 1336-43.
114. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Cir Res 2003; 92: 785-92.
115. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. PNAS USA 2000; 97: 2809-13.
116. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. PNAS USA 2001; 98: 1171-5.
117. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-5.
118. Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6: 191-3.
119. Martínez-González J, Badimon L. Influence of statin use on endothelial function: from bench to clinics Curr Pharm Des 2007; 13: 1771-86.
120. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007; 9: 175-83.
121. Ray JG, Norris CM, Udell JA, Tsuyuki RT, McAlister FA, Knudtson ML, et al. Lipid-lowering therapy and outcomes in heart failure. Cardiovasc Pharmacol Ther 2007; 12: 27-35.
122. Udell JA, Ray JG. Primary and secondary prevention of heart failure with statins. Expert Rev Cardiovasc Ther 2006; 4: 917-26.
123. Nakagawa T, Yokozawa T, Terasawa K, Nakanishi K. Therapeutic usefulness of Keishi-bukuryo-gan for diabetic nephropathy. J Pharm Pharmacol 2003; 55: 219-27.
124. Babu PV, Sabitha KE, Srinivasan P, Shyamaladevi CS. Green tea attenuates diabetes induced Maillard-type fluorescence and collagen cross-linking in the heart of streptozotocin diabetic rats. Pharmacol Res 2007; 55: 433-40.
125. Doughty RN, White HD. Carvedilol: use in chronic heart failure. Expert Rev Cardiovasc Ther 2007; 5:2 1-31,
126. Huang H, Shan J, Pan XH, Bao XF, Qian LB, Xia Q. Carvedilol Protects Early Diabetic Rat Hearts through Reducing Oxidative Stress. Conf Proc IEEE Eng Med Biol Soc 2005; 1: 929-32.
127. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J 2006;70:1001-5
128. Wang R, Miura T, Harada N, Kametani R, Shibuya M, Fukagawa Y, et al. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes J Pharmacol Exp Ther 2006; 318: 45-52.
129. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.Circulation 2007; 115: 1371-5.
130. Petrie MC, McMurray JJ. Dysglycemia and heart failure hospitalization: what is the link? Circulation 2007; 115: 1334-5.